RPG Life Sciences Limited (RPGLIFE.NS)
INR 2089.8
(-0.07%)
INR 2089.8
(-0.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.38 Billion INR | 23.51% |
| 2022 | 1.11 Billion INR | 25.79% |
| 2021 | 888.4 Million INR | 2.19% |
| 2020 | 869.4 Million INR | -3.57% |
| 2019 | 901.6 Million INR | -0.64% |
| 2018 | 907.4 Million INR | -33.53% |
| 2017 | 1.36 Billion INR | 48.09% |
| 2016 | 921.9 Million INR | 28.69% |
| 2015 | 716.4 Million INR | -0.15% |
| 2014 | 717.5 Million INR | 2.05% |
| 2013 | 703.1 Million INR | -45.72% |
| 2012 | 1.29 Billion INR | 19.1% |
| 2011 | 1.08 Billion INR | -6.29% |
| 2010 | 1.16 Billion INR | 12.75% |
| 2009 | 1.02 Billion INR | -8.91% |
| 2008 | 1.13 Billion INR | -10.46% |
| 2007 | 1.26 Billion INR | -3.84% |
| 2006 | 1.31 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -3.74 Billion INR | -371.59% |
| 2023 Q4 | 1.38 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 1.38 Billion INR | 23.51% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 1.25 Billion INR | 0.0% |
| 2022 FY | 1.11 Billion INR | 25.79% |
| 2022 Q4 | 1.11 Billion INR | 0.0% |
| 2022 Q2 | 963.7 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 934.8 Million INR | 0.0% |
| 2021 Q4 | 888.4 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 888.4 Million INR | 2.19% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 846.5 Million INR | 0.0% |
| 2020 Q4 | 869.4 Million INR | 0.0% |
| 2020 FY | 869.4 Million INR | -3.57% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q2 | 923.8 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 901.6 Million INR | -0.64% |
| 2019 Q4 | 901.6 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 907.4 Million INR | -33.53% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 1.15 Billion INR | 0.0% |
| 2018 Q4 | 907.4 Million INR | 0.0% |
| 2017 Q4 | 1.36 Billion INR | 0.0% |
| 2017 FY | 1.36 Billion INR | 48.09% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 1.21 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 921.9 Million INR | 28.69% |
| 2016 Q4 | 921.9 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 757.2 Million INR | 0.0% |
| 2015 FY | 716.4 Million INR | -0.15% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 800.6 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 716.4 Million INR | 0.0% |
| 2014 FY | 717.5 Million INR | 2.05% |
| 2014 Q4 | 717.5 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 849.8 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q4 | 703.1 Million INR | 0.0% |
| 2013 FY | 703.1 Million INR | -45.72% |
| 2013 Q2 | 822.7 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q4 | 1.29 Billion INR | 0.0% |
| 2012 Q2 | 2.58 Billion INR | 0.0% |
| 2012 FY | 1.29 Billion INR | 19.1% |
| 2011 FY | 1.08 Billion INR | -6.29% |
| 2010 FY | 1.16 Billion INR | 12.75% |
| 2009 FY | 1.02 Billion INR | -8.91% |
| 2008 FY | 1.13 Billion INR | -10.46% |
| 2007 FY | 1.26 Billion INR | -3.84% |
| 2006 FY | 1.31 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 783.82 Million INR | -76.085% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -377.91% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 60.629% |
| FDC Limited | 3.7 Billion INR | 62.79% |
| Gufic Biosciences Limited | 5.59 Billion INR | 75.353% |
| Hikal Limited | 12.99 Billion INR | 89.379% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 39.715% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 78.192% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -114.356% |
| Medico Remedies Limited | 438.24 Million INR | -214.939% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 87.697% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -763.753% |
| Sequent Scientific Limited | 8.27 Billion INR | 83.319% |
| Shilpa Medicare Limited | 12.93 Billion INR | 89.328% |
| Sigachi Industries Limited | 2.53 Billion INR | 45.474% |
| Themis Medicare Limited | 1.88 Billion INR | 26.877% |
| Unichem Laboratories Limited | 8.06 Billion INR | 82.896% |
| Venus Remedies Limited | 1.39 Billion INR | 0.905% |
| Wanbury Limited | 3.15 Billion INR | 56.261% |
| ZIM Laboratories Limited | 2.08 Billion INR | 33.669% |
| Lupin Limited | 96.23 Billion INR | 98.566% |
| Innova Captab Limited | 4.89 Billion INR | 71.832% |
| Ind-Swift Limited | 13.45 Billion INR | 89.741% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 71.646% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 99.093% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 90.206% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 62.301% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | 30.163% |
| Morepen Laboratories Limited | 4.45 Billion INR | 69.052% |
| Laurus Labs Limited | 42.71 Billion INR | 96.769% |
| Aarti Drugs Limited | 11.5 Billion INR | 88.002% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 73.36% |
| Alembic Limited | 1.43 Billion INR | 3.624% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 91.519% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 97.88% |
| Vaishali Pharma Limited | 371.16 Million INR | -271.858% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 83.272% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -365.09% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 97.747% |
| Eris Lifesciences Limited | 38.26 Billion INR | 96.393% |
| Windlas Biotech Limited | 1.76 Billion INR | 21.7% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.248% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -28.445% |
| Orchid Pharma Limited | 3.84 Billion INR | 64.095% |
| Albert David Limited | 1.15 Billion INR | -20.006% |
| Hester Biosciences Limited | 3.59 Billion INR | 61.605% |
| Sakar Healthcare Limited | 1.26 Billion INR | -9.255% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | 32.151% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 46.111% |
| Divi's Laboratories Limited | 18.99 Billion INR | 92.732% |
| Mankind Pharma Limited | 23.87 Billion INR | 94.219% |
| Neuland Laboratories Limited | 5.49 Billion INR | 74.899% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 87.111% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 98.078% |
| Wockhardt Limited | 39.87 Billion INR | 96.538% |
| Bal Pharma Limited | 2.51 Billion INR | 45.04% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.71% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | 34.552% |
| Alkem Laboratories Limited | 48.6 Billion INR | 97.16% |
| Valiant Laboratories Limited | 1.05 Billion INR | -30.422% |
| Ajanta Pharma Limited | 10.71 Billion INR | 87.113% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -111.597% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 19.858% |
| Granules India Limited | 22.95 Billion INR | 93.987% |
| Medicamen Biotech Limited | 940.36 Million INR | -46.772% |
| Ipca Laboratories Limited | 33.74 Billion INR | 95.91% |
| Brooks Laboratories Limited | 248.6 Million INR | -455.187% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -18.451% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.754% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 98.318% |
| NATCO Pharma Limited | 10.53 Billion INR | 86.895% |
| Suven Life Sciences Limited | 148.62 Million INR | -828.671% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 53.59% |
| Strides Pharma Science Limited | 37.68 Billion INR | 96.337% |
| Indoco Remedies Limited | 10.34 Billion INR | 86.655% |
| Alpa Laboratories Limited | 307.12 Million INR | -349.398% |
| Lasa Supergenerics Limited | 541.92 Million INR | -154.685% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 64.546% |